Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.54
-1.27 (-6.75%)
At close: Nov 17, 2025, 4:00 PM EST
17.58
+0.04 (0.23%)
After-hours: Nov 17, 2025, 7:59 PM EST
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
$1,759,267
Profits / Employee
-$197,897
Market Cap
1.84B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,372 | 58 | 4.41% |
| Dec 31, 2023 | 1,314 | 152 | 13.08% |
| Dec 31, 2022 | 1,162 | 322 | 38.33% |
| Dec 31, 2021 | 840 | -26 | -3.00% |
| Dec 31, 2020 | 866 | 123 | 16.55% |
| Dec 31, 2019 | 743 | 244 | 48.90% |
| Dec 31, 2018 | 499 | 244 | 95.69% |
| Dec 31, 2017 | 255 | 58 | 29.44% |
| Dec 31, 2016 | 197 | -73 | -27.04% |
| Dec 31, 2015 | 270 | 66 | 32.35% |
| Dec 31, 2014 | 204 | 58 | 39.73% |
| Dec 31, 2013 | 146 | 43 | 41.75% |
| Dec 31, 2012 | 103 | 5 | 5.10% |
| Dec 31, 2011 | 98 | 0 | - |
| Dec 31, 2010 | 98 | 35 | 55.56% |
| Dec 31, 2009 | 63 | -20 | -24.10% |
| Dec 31, 2008 | 83 | -42 | -33.60% |
| Dec 31, 2007 | 125 | 8 | 6.84% |
| Dec 31, 2006 | 117 | -6 | -4.88% |
| Dec 31, 2005 | 123 | 11 | 9.82% |
| Dec 31, 2004 | 112 | 6 | 5.66% |
| Dec 31, 2003 | 106 | 17 | 19.10% |
| Dec 31, 2002 | 89 | 4 | 4.71% |
| Dec 31, 2001 | 85 | 14 | 19.72% |
| Dec 31, 2000 | 71 | 15 | 26.79% |
| Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SRPT News
- 3 days ago - Sarepta Shares Jump After FDA Approves Updated Elevidys Label - Benzinga
- 3 days ago - Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information - Business Wire
- 3 days ago - US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries - Reuters
- 13 days ago - Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 - Seeking Alpha
- 13 days ago - Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance - Benzinga
- 13 days ago - Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It - Benzinga
- 13 days ago - Sarepta Therapeutics shares plunge after disappointing trial data - Invezz
- 13 days ago - Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking. - Barrons